
Emmanuel A Ho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8235203/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Segmented intravaginal ring for the combination delivery of hydroxychloroquine and anti-CCR5 siRNA nanoparticles as a potential strategy for preventing HIV infection. Drug Delivery and Translational Research, 2022, 12, 816-825.	5.8	2
2	Translational advancements in transdermal and mucosal delivery. Drug Delivery and Translational Research, 2022, 12, 733-734.	5.8	1
3	Fused deposition modeling three-dimensional printing of flexible polyurethane intravaginal rings with controlled tunable release profiles for multiple active drugs. Drug Delivery and Translational Research, 2022, 12, 906-924.	5.8	12
4	Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years. Materials Science and Engineering C, 2022, 133, 112623.	7.3	26
5	Reagent free detection of SARS-CoV-2 using an antibody-based microwave sensor in a microfluidic platform. Lab on A Chip, 2022, 22, 2307-2314.	6.0	12
6	Challenges in the development and establishment of exosome-based drug delivery systems. Journal of Controlled Release, 2021, 329, 894-906.	9.9	154
7	Microfluidic Technology for Antibacterial Resistance Study and Antibiotic Susceptibility Testing: Review and Perspective. ACS Sensors, 2021, 6, 3-21.	7.8	47
8	Sustainable Materials for Fused Deposition Modeling 3D Printing Applications. Advanced Engineering Materials, 2021, 23, 2001472.	3.5	38
9	Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention. Frontiers in Immunology, 2021, 12, 778455.	4.8	5
10	Anti-α ₄ β ₇ monoclonal antibody–conjugated nanoparticles block integrin α ₄ β ₇ on intravaginal T cells in rhesus macaques. Science Advances, 2020, 6, .	10.3	6
11	Autophagy induction and PDGFR-β knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection. Scientific Reports, 2019, 9, 1306.	3.3	23
12	Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. Journal of Controlled Release, 2018, 277, 102-113.	9.9	12
13	A new strategy for battling bacterial resistance: Turning potent, non-selective and potentially non-resistance-inducing biocides into selective ones. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 471-481.	3.3	9
14	Dynamic mechanical behaviour of nanoparticle loaded biodegradable PVA films for vaginal drug delivery. Journal of Biomaterials Applications, 2018, 32, 1119-1126.	2.4	15
15	Design and development of pH-responsive polyurethane membranes for intravaginal release of nanomedicines. Acta Biomaterialia, 2018, 82, 12-23.	8.3	32
16	Using safe, affordable and accessible nonâ€steroidal antiâ€inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. Journal of the International AIDS Society, 2018, 21, e25150.	3.0	21
17	Switchable On-Demand Release of a Nanocarrier from a Segmented Reservoir Type Intravaginal Ring Filled with a pH-Responsive Supramolecular Polyurethane Hydrogel. ACS Applied Bio Materials, 2018, 1, 652-662.	4.6	13
18	Current State of Microbicide Development. Clinical Pharmacology and Therapeutics, 2018, 104, 1074-1081.	4.7	16

Emmanuel A Ho

#	Article	IF	CITATIONS
19	Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Delivery and Translational Research, 2017, 7, 497-506.	5.8	102
20	Self-assembled nanoparticles made from a new PEGylated poly(aspartic acid) graft copolymer for intravaginal delivery of poorly water-soluble drugs. Journal of Biomaterials Science, Polymer Edition, 2017, 28, 2082-2099.	3.5	10
21	Reversibly pH-responsive polyurethane membranes for on-demand intravaginal drug delivery. Acta Biomaterialia, 2017, 47, 100-112.	8.3	39
22	Disposition, Metabolism and Histone Deacetylase and Acetyltransferase Inhibition Activity of Tetrahydrocurcumin and Other Curcuminoids. Pharmaceutics, 2017, 9, 45.	4.5	21
23	Nanoparticles Encapsulated with LL37 and Serpin A1 Promotes Wound Healing and Synergistically Enhances Antibacterial Activity. Molecular Pharmaceutics, 2016, 13, 2318-2331.	4.6	94
24	Protein/peptideâ€based entry/fusion inhibitors as antiâ€HIV therapies: challenges and future direction. Reviews in Medical Virology, 2016, 26, 4-20.	8.3	22
25	Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli. Antimicrobial Agents and Chemotherapy, 2015, 59, 7680-7686.	3.2	24
26	Biodegradable Film for the Targeted Delivery of siRNA-Loaded Nanoparticles to Vaginal Immune Cells. Molecular Pharmaceutics, 2015, 12, 2889-2903.	4.6	58
27	Fungicidal activity of AKWATON and in vitro assessment of its toxic effects on animal cells. Journal of Medical Microbiology, 2015, 64, 59-66.	1.8	5
28	Pharmacological effects of a C-phycocyanin-based multicomponent nutraceutical in an in-vitro canine chondrocyte model of osteoarthritis. Canadian Journal of Veterinary Research, 2015, 79, 241-9.	0.2	4
29	Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine. Drug Design, Development and Therapy, 2014, 8, 1801.	4.3	16
30	Development of an Analytical Method for the Rapid Quantitation of Peptides Used in Microbicide Formulations. Chromatographia, 2014, 77, 1713-1720.	1.3	6
31	Advancements in the field of intravaginal siRNA delivery. Journal of Controlled Release, 2013, 167, 29-39.	9.9	56
32	Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model. Journal of Pharmaceutical Sciences, 2013, 102, 227-236.	3.3	26
33	Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells. International Journal of Nanomedicine, 2013, 8, 2847.	6.7	25
34	Targeting the metabolism of leukemia stem cells as a novel therapeutic strategy. Drugs in Context, 2013, 2013, 1-2.	2.2	0
35	Characterization of Cationic Liposome Formulations Designed to Exhibit Extended Plasma Residence Times and Tumor Vasculature Targeting Properties. Journal of Pharmaceutical Sciences, 2010, 99, 2839-2853.	3.3	39
36	Drug release mechanism of paclitaxel from a chitosan–lipid implant system: Effect of swelling, degradation and morphology. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 149-157.	4.3	63

Emmanuel A Ho

#	Article	IF	CITATIONS
37	KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochemical and Biophysical Research Communications, 2007, 353, 679-685.	2.1	12
38	Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. Journal of Controlled Release, 2007, 117, 20-27.	9.9	57
39	Novel drug-delivery strategies for the treatment of ovarian cancer. Expert Review of Obstetrics and Gynecology, 2007, 2, 587-593.	0.4	0
40	In vivo disposition and stability of DNA frayed wires in mice. International Journal of Biological Macromolecules, 2006, 39, 310-316.	7.5	0
41	Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines. Current Cancer Drug Targets, 2006, 6, 295-311.	1.6	79
42	In vitro and in vivo characterization of a novel biocompatible polymer–lipid implant system for the sustained delivery of paclitaxel. Journal of Controlled Release, 2005, 104, 181-191.	9.9	63
43	Drug Delivery: Intravaginal, Advantages and Challenges. , 0, , 2712-2725.		0